Get the Stockscreener App
155.28
1.16%
-1.83
After Hours:
148.83
-6.45
-4.15%
Glaukos Corporation stock is traded at $155.28, with a volume of 452.06K.
It is down -1.16% in the last 24 hours and up +0.05% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$157.11
Open:
$156.77
24h Volume:
452.06K
Relative Volume:
0.80
Market Cap:
$8.53B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-52.46
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-1.57%
1M Performance:
+0.05%
6M Performance:
+33.02%
1Y Performance:
+66.41%
1-Day Range:
$152.50
$156.77
1-Week Range:
$152.50
$159.42
52-Week Range:
$83.90
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
155.28 | 8.53B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
How To Trade (GKOS) - Stock Traders Daily
Trust Point Inc. Has $972,000 Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) Short Interest Up 18.3% in January - MarketBeat
Piper Sandler raises Glaukos stock target to $180, keeps overweight By Investing.com - Investing.com Australia
Piper Sandler raises Glaukos stock target to $180, keeps overweight - MSN
Glaukos (NYSE:GKOS) Given Overweight Rating at Piper Sandler - MarketBeat
2,602 Shares in Glaukos Co. (NYSE:GKOS) Purchased by Avior Wealth Management LLC - MarketBeat
(GKOS) Trading Report - Stock Traders Daily
Glaukos (GKOS) Stock Forecast and Price Target 2025 - MarketBeat
Zweig DiMenna Associates LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today - Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 - BioSpace
Riverbridge Partners LLC Sells 163,751 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos (NYSE:GKOS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Glaukos stock soars to all-time high, reaches $161.17 - MSN
Glaukos stock soars to all-time high, reaches $161.17 By Investing.com - Investing.com Canada
Glaukos Co. (NYSE:GKOS) Short Interest Update - MarketBeat
Glaukos Co. (NYSE:GKOS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Position in Glaukos Co. (NYSE:GKOS) - Defense World
Oak Ridge Investments LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Personal Finance - Business Wire
Glaukos Shares Rise Amid Promising Trial Results - TipRanks
GKOS Stock Gains Following Positive Study Data on iDose Platform - MSN
(GKOS) Trading Signals - Stock Traders Daily
Glaukos reports sustained efficacy in iDose TR trials By Investing.com - Investing.com South Africa
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - BioSpace
Glaukos reports sustained efficacy in iDose TR trials - Investing.com
Glaukos Highlights Advances in Glaucoma Treatments - TipRanks
Glaukos says iDose TR showed sustained substantial IOP reductions in Phase 3 - TipRanks
Thomas Burns: The 2-Decade Bet That’s Paying Off - Orange County Business Journal
Here's Why You Should Add Glaukos Stock to Your Portfolio Now - MSN
Harbor Capital Advisors Inc. Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally? - MSN
Glaukos stock soars to all-time high of $153.72 By Investing.com - Investing.com Nigeria
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):